--- ADDS BROKER COMMENT FROM PANMURE GORDON AND SHARE PRICE ---
Scancell Holdings (LON:SCLP) hailed as a ‘ringing endorsement’ of its technology the publication of a paper describing the science behind its Moditope platform and the experimental results that support it.
The piece in the online edition of Cancer Research, a leading journal for doctors and surgeons specialising in this area of medicine, outlined the company’s innovative approach to generating vaccines that fight the disease.
The immunotherapy has generated a number of drug candidates, led by Modi-1, which is in later stages of pre-clinical development.
First-in-man studies will assess its potential to combat triple negative breast cancer, a strain that is resistant to current mainstream treatments.
Scancell’s joint chief executive, Professor Lindy Durrant, said: "The publication of this paper on the science behind Moditope in such a prestigious and widely read cancer journal is not only a great achievement for the research team at Scancell, it provides a ringing endorsement from the scientific community for this completely innovative approach to the treatment of cancer.
“This important paper lays out the foundation, rationale and experimental basis for the Moditope platform and its potential to generate effective cancer vaccines."
Panmure Gordon added: “We continue to consider the field of immuno-oncology as compelling and believe publications such as this potentially broaden the recognition of the company’s technical expertise.”
In particular, the broker noted that the paper should further widen the recognition of Scancell’s Moditope platform which is supporting the Modi-1 lead product through preclinical studies.
Moditope is one of two platform technologies being developed by the company.
The other, ImmunoBody, has generated a number of potential treatments in the emerging area of immune-oncology, where the immune system is used to fight cancer.
Chief among them is SCIB1, which has delivered highly encouraging early results when used in difficult-to-treat patients with melanoma.
Shares in Scancell were broadly flat at 19.75p on Tuesday.